Abstract
Introduction
Autoimmune inner ear disease is most often characterized by a bilateral (BPSNHL) or unilateral progressive sensorineural hearing loss (UPSNHL) that occurs over a period of week s to months, with or without vestibular symptoms and tinnitu s. This dise ase can also cause sudden sensorineural hearing loss (SSNHL).I Both pure-tone thresholds and speech discrimination scores (SDS) can be affected detrimentaIly. A predilection toward females has been reported, and the disease appears to have a higher incidenee in patients who have known autoimmune disease.?
The diagnosis of autoimmune sensorineural hearing loss (AISNHL) is ascertained by the history , clinical findings , response to immunosuppressive medication, and an immunologic evaluation of the patient's serum . Among the diagnostic tests that have been advocated are the lymphocyte transformation assay, the Westem blot analysi s for inner ear antibodies, and , most recently, supporting-cell immunofluorescence.v" The latter has been reported to be the most sensitive.Y An association between AISNHL and the presence of human leukocytic antigen (HLA) markers has also been proposed.? AIthough some controversy surrounds the interpretation of the Western blot assay for cochlear autoantibodies, the literature referenced elsewhere in this article, as weIl as our own clinical experience, suggests that it is one of the better tools available for establishing the diagno sis.
Spont aneou s improvement or resolution of untreated senso rineural hearing loss does not appear to occur often, at least in patients who experience a progressive loss. The most common outcome is a steady deterioration of both pure-tone average (PT A) and SDS valu es. However, most patients with suspected AISNHL confirmed by a positive Western blot assay do benefit from immunosuppressive medications, which are the mainstay of the treatment of AISNHL, ju st as they are for other immune-respon semediated disea ses . Pati ents who experi ence an objecti ve response to treatment tend to enjoy subjective impro vement , as weIl.
McCabe first reported the benefits of using a steroid and cyclophosphamide in 1979. 8 Seven year s later, Hughe s et . , -.
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Throughout the course of the treatment of these patients, our diagnostic and therapeutic strategies continued to evolve as paradigms were tested and modified. Today, we use both a steroid and a cytotoxic drug as an initial treatment for a high pereentage of our patients, as we will report in a future publication.
Patients and methods
We studied a group of 62 consecutive patients-32 males and 30 females, aged 5 to 87 years (mean: 50)----:-who were seen at the practice of the senior author (R.T.S.) for evaluation of suspected autoimmune inner ear disease and whose Western blot assays were positive for a 68 kD inner ear antigen.
Assessment ofhearing. Hearing loss was confirmed in 56 of the 62 patients (90.3%); tinnitus was present in 44 of these patients (71.0 %), vertigo in 30 (48.4 %), Meniere' s syndrome in seven (11.3 %), and Raynaud's disease in two (3.2%). Thi rteen patients (21.0 %) exhibited positive responses to at least one other autoimmune laboratory test-antinuc1ear antibody (n = 9), rheumatoid factor (n =3), antimicrosomal antibody (n =2),and anticardiolipin antibody (n = 1).
Of the 56 patients with confirmed hearing loss, 26 had BPSNHL (46.4 %),15 had UPSNHL (26.8%), and 15 had SSNHL. Of the six patients who did not have hearing loss (and who thus did not undergo drug treatment), three had tinnitus and fluctuating vertigo , two had fluctuating vertigo only, and one had unilateral tinnitus.
Patients were suspected of having AISNHL if they demon strated at least a 30-dB loss at three or more frequencies between 250 and 8,000 Hz (with or without a decrease in SDS) in addition to a subjective hearing loss in the affected ear(s) at the time of the initial audiogram. AISNHL was considered to be active if hearing at any frequency between 250 and 8,000 Hz deteriorated by at To be considered a responder , a patient had to meet one of these three objectives in at least one ear for (l) at l east ously specified dosage s. The duration of cyclophosphamide and azathioprine treatment was determined by the audiologic respo nse.
By the completion of the study, 12 of the 39 patients (30.8%) had received a steroid only, and 27 (69.2%) had received a steroid followed by a eytotoxic agent. Ten patients received more than one cytotoxic drug, but none received more than one such agent at a time. Every effort was made to wean all patients off their steroid before or during cytotoxic therapy .
Potential medication side effeets were reviewed with all patients prior to the start of cytotoxic therapy , and wome n of child-bearing age were informed that these medications are teratogenic. All patients underwent periodie comp lete blood cell count measurements and liver and renal function studies during treatmen t with a cytotoxic agent.
Air-eonduction (250 to 8,000 Hz) and bone-conduction thresholds (250 to 4,000 Hz) were measured during the initial visit, at least bimonthly during treatment, and after the completion of treatment in all patients . SDS values were obtained at the same time . The P:rA at 500 Hz, 1 kHz, 2 kHz , and 3 kHz was calculated for all patients prior to therapy, during any response period, and post-therapy. Subjective improvement in hearing and alleviation of vertigo and tinnitus were also recorded for each patient.
Assessment of response. Three criteria were used to assess each patient 's response to drug treatment: Of the group of 62 patients, 14 were found to have an inactive hearing loss, and thus they were not treated with immunos uppressive medications; four others were lost to follow up before their active or inactive status could be determined. Of the 44 patients who were identified as having an active hearing loss, 39 agreed to undergo treatment with immunosuppressive therapy (the remaining five patients decline d treatment).
Among the group of 39 patients , 20 (51.3 %) had BPSNHL, 11 (28.2%) had UPSNHL, and eight (20.5%) had SSNHL.
HLA A, B, and C typing data on 44 patients were available for'analysis , and HLA DR data on 36 patients. The presence or absenee of four specific antigens-HLA B35, CW4, CW7, and DR4-was determined so that we could analyze the proposed association with AISNHL (the presence ofB35, CW4, and CW7 and the absen ce of DR4).7 HLA B35, CW4 , and CW7 were present in 13 (29.5 %), 14 (31.8%), and 22 (50.0%) of the 44 patie nts, respectively. HLA DR4 was absent in 29 of the 36 patients (80.6 %).
Finally, all patients had a cerebellopontine angle tumor ruled out by gadoli nium-enhanced magnetic resonance imaging of the brain and internai auditory canals.
Drug treatment. Initially, all 39 patients received an oral steroid ; 34 receive d approximately I mg/kg/day of prednisone for 2 to 12 weeks, four patients received an equivalent dosage of dexamethasone for 2 weeks, and one patient received an equivalent dosage of methylprednisolone for 2 weeks.
After the initial steroid trial, cytoto xic treatment was offered to those patients who did not improve and to those who did respond initially but whose improvement was not sustained as the steroid was tapered and discontinued. A total of 27 patients elected 1oo T-----------------~;::::======t o recei ve a eytotoxic agent. Of these, 21 were started on 7.5 to 15 mg/wk of oral metho trexate for at least 6 months uniess toxicity or a lack of respo nse necessitated an earlier termination of treatment; the remaining six were started on oral cyclophosphamide at 100 mg twice a day .
Those who did not respond to methotrexate or who relapsed during therapy were offered the opportunity to switch to oral cyclophosphamide or oral azathioprine, both at 100 mg twice a day. Those ... 
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2 consecutive weeks at some point following the completion of steroid therapy or (2) a minimum of 2 month s following the cessation of cytotoxie therapy. The result of each patient ' s initial audiogram was used as the baseline from which any improvement of decline in pure-tone threshold or SDS could be measured . A paired two-tailed Student' s t test was used to deteet any statistically significant differences (p<0.05) in pre-and post-treatment PTA and SDS values. Contro l gro up. To establish a basis for comparison, we reviewed our reeords for the earliest available PTA and SDS data on the 39 patients who eventually underwent drug treatment. Adequat e pretreatment audiometric data were available on 15 of these patients (22 ears), and they essentially served as their own controis during an extended period of time prior to the initiation of treatment. Ten of these patients had had audiometric data measured at 3-month intervals, three at 6-month intervals, and two at l-year intervals.
The duration of evaluation of these patients prior to the start of this study ranged from 6 weeks to 15 years (mean: 2.7 yr). The duration of the documented hearing loss was Volume 80, Number 11 greater than 3 years in six ears and less than 3 years in 16 ears . Pretreatme nt audiometric data were available on seven patients who were awaiting their Western blot assay results. Fourpatients had been refer red from outside otolaryngologists without having undergone previous immunosuppressive therapy. Of these four referrais, one patient had received conservative medical treatment for suspected Menie re' s disease, one was presumed to have coehlear otosclerosis and was treated with auditory rehabilitation, and two had undergone auditory rehabilitation only .
During the early 1980s, we had treated two of these 15 patients for suspected Meniere' s disease; we administered conserva tive medical therapy followe d by endolymphatic sae decompressio n. Both of these patients subsequently underwent Western blot analysis when it became available. One of our patien ts had undergone surgica l treatment for bilateral chronic otitis media, and another had undergone a congenital atresia repa ir with reseetion of cholestea toma prior to Western blot analysis. In addition to the early audiometric data on these 15 patients who underwent treatment, we also obtained adequate early 8 15 LASA K, SATALOFF, HAWKSHAW, CAREY, LYO NS, SPIEGE L Table 2 . Mean pretr eatment and response PTA and 50S val ues for ears treated with cyt otox ic age nts f oll owi ng stero id t herapy n (%) dat a on four of the fiv e eli gible patients who declined tre atment. Am ong the 27 patient s who we nt on to cy totox ic therap y, 21 (77.8 %) had fail ed stero id therapy outrig ht; the other six patients (22 .2%) had responded initially, but their hearing later deteriorated as the stero id wa s tapered and discontinued. Therefore, a total of 12 of the 39 patients (30.8 %) did exhibit some initial response to steroid therapy, althou gh the response wa s sustaine d in onl y six (15.4%).
Prior to the initi ation of treatment, the mean he aring deficit had be en mo re severe (i.e., higher PTA and lower SDS values) among those who ultimat ely required cytotoxic therap y than in those who received a ster oid onl y (table 2) . Following cytotoxic therapy, the 17 pat ients who responded experienced a modest improvement in me an PT A (4 .5 dB) and a more pronounced improvement in me an SDS (26 .2%) (figure s 2 and 3). Conversely, the six responders in the ste roid-only group had a substanti al improvement in me an PT A (14 .8 dB ) and a sma ll improvement in SDS (6.9 %). Subj ective assessme nts of hearing improvement were avail able for 21 of the 23 patients w ho responded to treatment. Subjective improvement was reported by 19 of these 21 responders (90 .5%) . Alleviation of symptoms wa s reported by 10 of the 20 patients (50 .0% ) who had pretreatment vertigo and by seven of the 34 (20 .6%) with pretreatment tinnitus.
There was no report of subj ec tive improvement by an y of the 16 patients who did not respond to either ther apy . Their mean pre-and post-treatment PTA values were 64 .8 and 67 .6 dB , respectively, and their co rres ponding SDS va lues wer e 49.6 and 47.5 %.
Steroid. Among the 12 patients who rece ived on ly a steroid, six had BPSNHL, two had UPSNHL, and four had SSNHL. Th e duration of steroid therapy ranged from 2 weeks to 3 months (mean: 3 wk). Among the six patients whose treatment was successful (a to tal of seven tre at ed ea rs), the onset of a po sitive re sponse was ob ser ved bet ween 3 and 29 days (mea n: 14) after the initiation of trea tme nt.
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Th e' six patients in the steroid-only gro up who failed therap y de clined further treatment. Azathioprine. Seven patients received azathioprine, none as a first-line cytotoxic medication. One of these patients had previously responded to both methotrexate and cyclophosphamide but was forced to discontinue both drugs because of elevated liverenzyme levels; this patient subsequently responded to azathioprine. Another patient had also been treated previously with methotrexate and then cyclophosphamide but relapsed after an initial response to each ; this patient also responded positively to azathioprine. The other five patients had been treated previously with methotrexate only. Two of them had responded initially to methotrexate but relapsed when it was discontinued; both ofthese patients responded subse- 
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and to two patients following steroid and cyclophosphamide therapy , Of these 23 patients , 13 had BPSNHI..;, eight had UPSNHL, and two had SSNHL. The duration of methotrexate treatment ranged from 1 to 30 months (mean : 7.3).
Among the 14 patients (60.9 %) whose treatment was successful (17 ears), the onset of a positive response was seen between 6 days and 6 months (mean: 42 days) after the initiation of methotrexate Response treatment.
Of the two patients who received methotrexate as a second-line cytotoxic agent, one had responded to cyclophosphamide initially, relapsed when it was discontinued, and then responded to methotrexate. The other patient failed both cytotoxic agents.
Cyclophosphamide. In all, cyclophosphamide Figure 3 . Mean SDS values before and after treatiilent in ears that was given to 10 patients-six as an initial cytotoxic respanded to variaus therapeutic regimens. medication and four as a followup to methotrexate. Among the four patients in the latter group, two had responded initially to methotrexate but were forced to discontinue treatment because of elevated Iiver enzyme levels, one had responded but then relapsed, and one failed methotrexate outright. Three of these four patients responded subsequently to cyclophosphamide, including two previous methotrexate responders and the one methotrexate failure. Of the 10cyclophosphamide patients , six had BPSNHL, two had UPSNHL, and two had SSNHL. The duration of cyclophosphamide treatment ranged from I to 9 months (mean: 2.7).
Among the five patients (50.0 %) whose treatment was successful (seven treated ears), the onset of a positive response was seen between 30 and 90 days (mean: 58) 
Safety considerations
• The most frequently reported adverse events associated with the pharmacologic action of a muscarinic agonist (>1 0% incidenee) in clinical trials of eevimeline were: excessive sweating, nausea, rhinitis, and diarrhea. Gonsult the brief summary of prescribing information for other adverse events
• Gevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to the drug, and in acute iritis and narrow-angle (angle-closure) glaucoma • Gonsult the brief summary of prescribing information for safety considerations concerning drug interactions,
If left untreated, the dry-mouth symptoms of Sjögren's syndrome can lead to more serious medical problems'"
• Compromised nutrition uleer, periodontal destruetion, reetal disorder , st omatit is, tenesmus, tonque diseoloration, tonguedisord er , geographie tongue, tongue ulceration, dent alcaries EndoerineDisord ers: inereased glueoeortieoids, goiler , hYPO lhyroidism HemalologieDisorders:thromboeytopeniepurpura, thromboeythemia, thromboeytopenia, hypoehromieanemia, eosinophilia, granuloeytopenia, ieueopenia, leukoeytosis, eervieal lymphaden opathy, Iymphadenopathy LiverandBiliary SyslemDisorders: eholeli thi asis, inereased gamma-gl utamyl transferase, inereased hepatieenzymes, abnormal hepatielunetion, viral hepalilis, inerease dserumglutamat eoxaloaeetietransaminase(SGOT)(also eall ed AST-aspartateaminolransferase), increased serumgiutamatepyruvat etransaminase (SGPT)(aisoeall edALT-alani ne aminotransferase) Melabolieand Nulrilional Disorders: dehydration, diabetes meilitus, hyperealeemia, hyper eholesterolemia, hyperglyeemia, hyperlipemia, hypertrigl yeerid emia, hyperurieemia, hypoglyeemia, hypokalemia,hyponatremia, Ihirst Museuloskelelal Disorders : art hri tis, agg ravatedarthritis, arthropathy, lemoral head avaseularneerosis, bone disorder , bursit is, costochondritis, plantar fasciitis, muscl eweakness, osteomyelitis, osteoporosis, synoviti s, tendinitis, tenosynovitis Neopfasms: basal eelica rcinoma, squamous carcinoma Nervaus Oisor ders: carpal tunnelsynd ro me, coma, abnormal coordination, dysesthesia, dyskinesia, dysphonia, agg ravatedmultipl esclerasis, involuntarymusclecontractions, neuralgia, neuropathy, paresthesia, speechdisorder, agita· tion, conf usion, depersonalization, aggra va teddepression,abnormal dreaming, emotional lability, manicreaction, paroniri a, somnolence, abnormal thinking, hyperki nesia, hallucination Mi seellaneous Di sorders: fail, foodpoisoni ng, heal stroke, joi nt disloeation, posl-oper ativehem orrhage Resisl ance MechanismOisorders: eell ulitis, herpes simplex, herpeszoster, bact erial inl ection, viral inlection, genital rnoniliasis, se psis Re spiraloryDisorders:asthma, bronehospasm, ehronieobstruetive airwaydisease, dyspnea, hemoptysi s, laryngili s, nasal ul eer, pl eural etlusion, pl eurisy, puimonaryeongestion,puimonarylibrosis, resplratory disorder RheumalologieDisor ders: ag gravated rheumatoid arthriti s,lupuserythe matosusrash, lupus erythe malosus syndrome SkinandAppendagesDisorders: aene, alopeeia, burn, dermatitis, eo ntaet dermatilis, Ii ehenoid dermalitis, eezema, furuneu losis, hyperkeratosi s, liehen pl anus, nai I di seoioration, naiI di sorder , onyehia, onyehomyeosis, par onyehia, photosensitivity reaction, rosaeea, scl erod erma, seborrhea, skindiscolorat ion, dryskin, sk inexfoliation, skinhypertrophy, skinul ceration , urtiearia, verruca,bullou seruption, coldelammy skin Spec iaJ SensesOi sorders: deafness, decreased hearing , motionsi ckness , parosmia, tasteperversion, blepharitis, cataraet, corneal opaci ty, comeal ul eeration, diplopia, gl aucoma,anteriorchamber eye hemorrhage, ker atitis, ke ratoconjunctivi lis, mydriasis, myopia, photopsi a, retinaideposits, retinaIdisorder, seleritis, vitreous delachm enl, tinnitus Urogenila' Dlsorders:epi didymilis, prostatiedi sorder , abnormal sexual funetion, amenorrhea, femalebreaslneoplasm, malignant female breast neoplasm, femalebreast pain, positivecervieal srnear test, dys menorrhea, endometrial disorder , intermenstrual bl eeding, leukorrhea, rnenorrhagia, mensl rual disorder, ovariancyst, ovari an disord er , genitalpruritus, uterinehemorrhage, va ginal hernorrhage, atrophicvagini lis, albumi nuria, bladder discomfort, inereased blood urea nitrag en , dysuria, hematuria, micturitiondisorder, nephrosis, nocturia, inereasednonprateinni trogen, pyelonephritis, renal caleulus, abnormalrenalfunction , renal pain , st rangury,urethral di sorder , abnormal urine, urinaryincontinence, de creased urineflow, pyuria In one subjeel wilh lupus erythematosus reeeiving eoneomitant multipl edrug ther apy, a highly eievatedALTlevelwas notedafterthe fourthweek ofeevimeli ne therapy. Intwoothersubjeets reeeiving eevimelineinIheelinieal lriai s, very high ASTlevel s were noted. Thesignifieanee at thesefindings is unknown. Additional adverse events(relat ionship unknown) whiehoeeurred inother elinieal studies (patienl population ditl erent from Sjõgren'spatient s)are asfoll ows: eholinergiesyndrome, blood pre ssurefluetualion, eard iomegaly, posturai hypotension, aphasia, eonvulsions, abnormal gait, hyperesthesia, paral ysis, abnormal sexualfunetion, enlarged abdomen, ehangein bowel habit s, gum hyperpl asia, intestinaiobslruetion,bundle branehbl ock, increased creatinephosphokinase, eieetrolyteabnormality, gl yeosuria, gout, hyperkal emia, hyperprotei nemia,inereased laeliedehydrogenase(LDH), inereasedalkaline phosphalase, faiiure tothrive, abnormal pl ateiets, ag gressive reaetion, amnesia, apathy,delirium, delusion,dementia, iIIusion, impotenee, neurosis,paranoidreaction , personalitydi sorder , hyperhem oglobi nemia,apnea, ateleetasis , yawning, oliguria,urinary relention, distended vein,Iymphoeytosis MANAGEMENT OF OVEROOSE: Managementof the si gns and symptoms ofaeule overdosage should be handl edin a manner eonsistent withthat indicat edfor other musearinicagonists:generalsupportive measuressh ouldbeinstituted. If medieally indieal ed, at ropine, ananli-eholi nergieagenl may beof valueasan antidotefor emergeneyuse in palients who havehadanoverdose of eevimeline. II Drugs whichinhibit CYP2D6and CYP3A3/4 also inhibit themetabolismof eevi meiine. Cevi meline shouIdbe usedwith eautionin individuals known or suspeet edto bedeliei ent inCYP2D6 aetivity, based onpreviousexperience, asthey may be ata higher risk of adverseevents. Inan in vil fO study, eytoehrome P450 isozymes l A2, 2A6, 2C9, 2C19, 2D6, 2El, and 3A4 Vl erenot inhibited by exposure 10eevimeline.
Carei nogenesis, Mulagenesis and Impalrmenl 01 Ferlilily:
Li fetimeeareinogenieity studies wereeondueled inCD-l mieeand F-344 rats. Astalistieally significant increaseinthe incidenee of adenocareinomasofthe uterus wasobserved inlemal eratsIhatreeeivedeevimeline at adosage of 100 mglkg/day (approximatel y 8timesthe maximum human exposurebasedoneomparisonofAUC da la). No other signifieantditler ene esin tumorincidenee wereobservedin either mieeor rats.
Cevimelineexhibited noev idenee of mul agenieityorelastogenieityin abatt eryof assa ysthatineludedanAmes lesl, an in vilroehrom osomai aberration study in mammal ian eelis, amouseIymphomastudy inL51 78Yeelis, or amieronucleus assayconducted invivo in ICRmiee. Cevimel inedid not adversely atl eetthereproduelive performance orfertiiityof male Sprague-Dawl ey rats whenadministeredfor 63days prior to mating and throughouttheperiod of matingatdosages upto45 mglkg/day (approximately 5 limesthe maxi mumreeomm ended dose fora60kg human following normalizationof thedataonthe basis 01body surfaee area estimates). Femal es that were treated with eev imelineatdosages upto 45mglkg/day Irom14daysprior tomat ingthroughday sevenof gestati onexhibitedastatistieall y signilieantl y smaller numberof impl antations thandid contral animals. Pregnancy: Pregnaney Cal egoryC. Cevimeline\'las associatedwitha reduclion inthemean numberofimpl antationswhengi ven topregnantSpragueDawley rat slrom 14 days priorto matingthroughday seven 01gestalion at adosage of 45mglkg/day (appr oximatel y 5 times themaximum reeomm end ed dosefora60kghuman wheneompared onthebasis ofbody surlaee area estimates). Thiseffeetmay have been secondary to maternai toxiei ty.Ther eare noadequat eandwell-eontrolled stu di es in pregnant women. Cev imelineshould beused during pregnaney only if the potential benelit justilies thepotential risk 10 thefelus. Nursi ngMolhers : It isnot known whether thisdru gisseeretedinhumanmilk. Beeau semanydrugs are exeretedin humanmilk, and beeause of the potentiai forseriou sadverse reaetions in nursinginfants from EVOXACTM, adeeisi on shoul d bemade whet her to diseontinuenursing or diseontinue thedrug , taking inloaeeount theimport aneeofthe drugtothemother. PedlalrleUse: Sal etyand etleetivenessin pediatriepatients havenot been established. Gerl alric Use: Al though eli nieal studi esateevimelineineiuded sUbjeets overtheageof65, thenumber s wer enotsuffieien t todeterminewhether they res ponddi fferen tiy lromyounger sUbjeets. Speeial eare shoul d beexereisedwhen eevimelinetreatmen t isinitiat edin anel der ly pati ent, consideringthe greater frequeney of deereased hepatie, renal , or eardiae funetion, and of eoneomil anl disease or other drug therapy inIheelderly. AOVER SE REACTlON S: Cev imeline was admi ni steredto 1777 pati entsduring elinieallrials worldwide, ineluding Sj ilgren's patientsand patienls with olhereondilions. Inplaeebo-eontroiled Sjõgren'sstudies inthe U.S., 320 patients reeeivedeevimeline doses rangingfrom 15 mgtidto60mgtid, ofwhom93% werewo menand7%weremen, Demographi edislribution was 90%Cau easian, 5%Hispanie, 3%Black, and2%of olherorigin. quently to azathioprine. The other three patients had failed methotrexate therapy; one responded subsequently to azathioprine. Of the seven azathioprine patients, three had BPSNHL, three had UPSNHL, and one had SSNHL. The duration of azathioprine treatment ranged from 6 weeks to 20 months (mean : 7 mo). Among the five patients (71.4%) whose treatment was successful (five ears), the onset of a positive response was seen between 30 and 90 days (mean: 51) after the initiation of azathioprine treatm ent.
Steroid vs eytotoxie therapy. We used the paired twotailed Student' s t test to compare any significant differences in changes in PTA and SDS that were observed during the initial steroid trial with those that were observed following cytotoxic therapy. All ears treated with both a steroid and a cytotoxic agent were included in this analysi s. Any significant (according to the criteria established earlier) decrease in PTA or increase in SDS was considered to represent improvement.
During the initial steroid trial, hearing in all ears generally deteriorated; the mean PTA rose 0.85 dB and the mean SDS fell 3.3% for all ears. Conversely, overall hearing improve d during cytoxic therapy; the mean PTA felll .9 dB and the mean SDS rose 11.1%. The difference in PTA before and after cytotoxic therapy approached but did not reach statistical significance (p =0.056), while the difference in SDS was statistically significant (p<0.0l).
Methotrexate. We also evalu ated each cytotoxic medication individually. During steroid therapy, all ears that were eventually treated with methotrexate as the initial cytotoxic agent experienced a mean decrease in PTA of 0.68 dB and a mean decrease in SDS of 1.4%. Following methotrexate therapy , the mean PTA fell 2.6 dB and the mean SDS rose 11.5%. The difference in PTA was not statistically significant (p = 0.27), but the impravement in SDS was (p<0.01).
Cycl op/zosp/zamide. During steroid therapy for ears that were eventually treated with cyclophosphamide as a first-line cytotoxic agent, the mean PTA rose 4.4 dB and the mean SDS fell 9.5%. Following cyclophosphamide therapy, the mean PTA felll.3 dB (p = 0.13) and the mean SDS rose 10.5% (p<0.01).
Azathioprine. The mean PTA rose 0.40 dB and the mean SDS remained unehanged following steraid therapy . Following azathioprine treatment, the mean PTA fell 0.33 dB (p =0.749) and the mean SDS rose 10.4% (p =0.061).
Side effe cts. Sixteen of the 39 treated patients (4 1.0%) reported a total of25 medication side effects (table 3). All of these adverse events were resolved by discontinuing the offe nding agent and by initiating appropria te medical intervention when necessary .
Control group. The pretreatment audiometric analysis is a crude control tool, but it helps define the natural history of AISNHL. We compared the early PTA and SDS values of the 15 patients in the control group with those that were later obtained during audiometric testing administered ju st prior to the institution oftherapy (table 4) ; we did the same for the four controls who refused treat- (table 5) . The early audiograms were also evaluated to determine whether any of our three response criteria had already been met by any of these controIs during the pretreatment period.
Of the 15 controIs who underwent therapy, seven had BPSNHL and eight had UPSNHL (total: 22 ears) . On average, these control patients did not experience any spontaneous improvement. During the pretreatment period, their mean PTA rase 4.7 dB and their mean SDS drapped 5.8 %. Onlyone of the 22 ears (4.5%) spontaneously met any of the response criteria for audiometric impravement, and that impravement lasted only 2 months .
It is interesting that of the six ears that had had a documented hearing loss for at least 3 years, onlyone (16.7%) responded to immunosuppressive therapy. Conversely, 15 of the other 16 ears (93.8%) met at least one of our response criteria following immunosuppressive therapy. Thus, as McCabe has suggested, there might be a window of opportunity to treat AISNHL before irreversible inner ear damage occurs."
The early audiometric data on the five eligible patients who declined treatment revealed that one had BPSNHL, two had UPSNHL, one had bilateral SSNHL, and one had unilateral SSNHL. Data on four of these patients were adequate to include in our analysis.
The patient with unilateral SSNHL reported a spontaneous resolution of the hearing loss prior to our evaluation, which was confirmed by audiometric testing in our office. However, the original audiogram was not available for our review, and therefore this patient was not included in our final analysis.
The patient with bilateral SSNHL had a flat, moderate loss on the right and a flat, mild loss on the left; her speech discrimination was preserved, and she did not experience any vertigo. Over the course of I month after she had declined treatment, this patient experienced a spontaneous and complete resolution of her hearing loss in both ears. Prior to being lost to followup, she had satisfied response criteria I and II in both ears for a period of 2 months .
One of the two patients with UPSNHL had a moderate loss on the right and an SDS of 88%. Over 5 months, her hearing had improved to the point that it was only mild, and her SDS had risen to 100%; even so, this patient met none of the response criteria. Th e other patient with UPSNHL had a mild hearing loss and an SDS of 88%. Over the following year, his hearing had pro gre ssively det eriorated until it had become modera tely severe, and his SDS had fallen to 52 %.
Th e pati ent with BPSNHL had a mode rate loss in both ears; her SDS values on the right and left were 84 and 88%, res pec tively. No further deciine in her hearin g was noted over the 3 month s prior to her loss to followup.
Discussion
Th e presenc e of antibodie s to inner ear antigens in patients with sudden or rapidly pro gre ssiv e sensorineura l hearing loss supports the concept that an autoimmune response is responsibl e for inner ear disease in these patients. In 1987, Harri s con firmed that guinea pigs immun ized with bovine cochlear tissue experienced se nsorineural hearing 10SS.11 Further evidence has sugg ested that AISN HL is associated with the presenc e of an antibody to a 68 kD inner ear prot ein (isolated by We stern blo t assay) .? Although it had been sugges ted that the cochlear anti gen in que stion is heat shock prot ein 70 (HSP 70), Trune et al reported that mice inoculated with HSP 70 did ,not exhibit a shift in auditory brain stem response despit e the fac t that they mount ed an adequate immunologic response." Ha rris and Ryan found that the sera of 32 % of pati ent s with a rapidly progressive sensorineura l hearing loss showed a reaction to a 68 kD antigen.? Hu ghes et al found that 86% of their suspected AISNHL patients had sera that reacted with a 68 kD antige n,13and Mo scicki et al reported that 58% of their patients possess ed such antibodies.!' Nair et al repo rted that the monocional antibody KHRI-3, which bind s to an inner-ear-supp orting eeli antigen , ca n lead to sensorineural he aring loss in animais that ha ve high KHRI-3 serum titer s and in tho se that rec eiv e antibody infu sed directly into the inn er ear. 15 . 16 Di sher et al reported that KHRI-3 precipitate s a 68-70 kD antige n that bind s hum an antibodies in the sera of suspec ted AISNHL patients.' ?Di sher et al also show ed that sera from patient s with AISNHL cont ain antibody to inn er-ear-supportin g eelis, and they hypothesize that this is the same anti gen as that defined by KHRI -3.
Mcf'abe was the first to recognize AISNHL,8 AIthou gh the treatment of suspected AISNHL has not been
The topieal enesthetic of choice -- In the present study , we did not find a female preponderance to suspected AISNHL , as has been suggested previously. ' We did find that 21.0% of our patients tested positive on autoimmune laboratory testing, a figure that is consistent with others reported in the literature.F' Our HLA findings that B35, CW4, and CW7 antigens were present in 29.5,31 .8, and 50.0% oftested patients, respectively , and that DR4 was absent in 80.6% oftested patients are similar to those previously reported by Bowman and Nelson,' and they further support the praposed association of these antigens with AISNHL.
HUBBl eAIN E
It is interesting to note that the six patients in the steroidonly group who responded to treatment had, on average , a lesser degree ofhearing loss prior to therapy (PTA: 48.1 dB; SDS 69.1%) than did those who responded to eytotoxic therapy (PTA: 64.2 dB; SDS: 47.9%). The steroid responders also tended to experience a greater impravement in mean PTA (14.8 dB) than did those who responded to cytotoxic medications (4.5 dB). Conversely, the cytotoxic responders had a greater impravement in mean SDS (26.2%) thandid the steroidresponders (6.9%). Improvements in PTA during cytotoxic therapy were not significantly different (p = 0.056) from the changes observed in these patients during their steroid trial. However, the impravement in SDS was significant (p<0.01). This finding suggests that chanee is a highly unlikely explanation for the impravement in SDS during cytotoxic therapy .
The mean duration of response according to criterion III ( 20% impravement in SDS) in the cytotoxic group was 1004 months. However, no conelusions can be drawn coneerning a comparison of SDS response duration between the cytotoxic and steroid groups because of (1) the short interval that passed between the beginning of the steroid trial and the initiation of cytotoxic treatment (-1 mo) and (2) the fact that onlyone patient in the steroid-only group met criterion III.
Overall, patients tolerated therapy well. Only three cases of a major side effeet were observed during this study; one patient experienced hemorrhagic cystitis while 822 taking cyclopho sphamide, and one patient each experienced lymphoblastic vasculitis and pancytopenia/sepsis while taking azathioprine. All major side effect s resolved upon termination of therapyand appropriate medical intervention. Although methotrexate had to be discont inued in five patients beca use of a rise in liver enzyme levels, azathioprine appeared to be the most toxic of the four medications used in the study .
